Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study Post published:August 8, 2023 Post category:Press Release
MIND CURE ANNOUNCES CLOSING OF LNG ENERGY’S SUBSCRIPTION RECEIPT FINANCING Post published:August 5, 2023 Post category:Press Release
Natural Medicine Advisory Bulletin #2: July 2023 Post published:August 3, 2023 Post category:Colorado Natural Medicine Advisory Bulletin
COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights Post published:August 3, 2023 Post category:Press Release
Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement Post published:August 2, 2023 Post category:Press Release
Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement Post published:August 1, 2023 Post category:Press Release
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio Post published:August 1, 2023 Post category:Press Release
Optimi Completes Proprietary Natural Psilocybin Extraction Process and Files U.S. Provisional Patent Post published:August 1, 2023 Post category:Press Release
Psychedelic Bulletin #142: Terran’s IP Portfolio; AMA Advocates Against Non-Medical Psychedelics; Couple Receives First Psilocybin Services in Oregon; Mass. Ballot Measure Ramps Up; NIDA and NIMH Directors Opine Post published:July 31, 2023 Post category:Psychedelic Bulletin
COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023 Post published:July 31, 2023 Post category:Press Release